BRIEF—Adocia partners for insulin Lispro in China

French biotech firm Adocia has entered into a strategic partnership with Tonghua Dongbao Pharmaceuticals, granting the Chinese firm exclusive development and commercialization rights to the BioChaperone Combo and ultra-rapid insulin BioChaperone Lispro in China and other designated areas.

Adocia will retain the rights for the two projects in the rest of the world.

Under the agreement, Adocia will receive an upfront payment of $50 million and milestone payments of up to $85 million.

Adocia is also expected to receive double-digit royalties on the sale of both products in the territories.

The BioChaperone Combo will likely be the most important program for the collaboration, as premixes are the most popular insulin treatments in China, the French company stated.